<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790516</url>
  </required_header>
  <id_info>
    <org_study_id>2010-439</org_study_id>
    <nct_id>NCT01790516</nct_id>
  </id_info>
  <brief_title>Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer</brief_title>
  <official_title>A Pilot Prospective Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with newly diagnosed head and neck cancer that cannot be removed
      by surgery.

      The purpose of this study is to determine the feasibility of using genetic variations in
      patients to select the right drug to treat head and neck cancer. Cisplatin and cetuximab
      (Erbitux)are both approved by the FDA to treat head and neck cancer in combination with
      radiation therapy. In this study the investigators will test whether genetic differences
      between patients can be used to pick which of these two drugs a patient should receive. All
      patients will have a blood sample drawn that will be tested for genetic differences. If
      patients have genetic differences that correlate with a better outcome from cisplatin they
      will receive cisplatin with radiation. If patients have genetic differences that do not
      correlate with a better outcome from cisplatin they will receive cetuximab with their
      radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment-naive patients with locally advanced, non-metastatic (Stage III to IVB) squamous
      cell carcinoma of the head and neck who are candidates for concurrent chemoradiotherapy as
      primary therapy with curative intent will be enrolled. Patients will be genotyped for
      germline variations at four SNP loci in three genes involved in DNA nucleotide excision
      repair (ERCC1, ERCC2, and XRCC1). Patients with 3 to 8 variants will receive cisplatin (Arm
      A). Patients with 2 or fewer variants will receive cetuximab (Arm B).

      The hypothesis of the study is that prospectively testing patients for variations in DNA
      repair enzymes to determine whether to use cisplatin or cetuximab in locally advanced head
      and neck squamous cell cancer is feasible.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accruals--2 patients were enrolled in over a year
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Returning Genetic Testing Results in a Timely Manner to the Treating Physician</measure>
    <time_frame>20 months</time_frame>
    <description>Feasibility is defined as follows:
- Patients' genetic test results are returned to the treating physician within 3 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Head and Neck Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <other_name>Cispaltin</other_name>
    <other_name>Platinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.</description>
    <arm_group_label>Cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>daily radiation for 7 weeks</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_label>Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven squamous cell carcinoma of the head and neck, including the oral cavity,
             oropharynx, hypopharynx, or larynx, but not including primary tumors of the
             nasopharynx, sinuses, or salivary glands.

          -  Locally advanced, Stage III to IVB disease, and a candidate for primary therapy using
             chemotherapy and radiation therapy with curative intent.

          -  Patients with a diagnosis of 'unknown primary' will be eligible if chemoradiotherapy
             is the primary modality of treatment

          -  No previous chemotherapy, radiation, or surgery for their diagnosis of head and neck
             cancer

          -  Eastern Cooperative Oncology Group performance status &lt;/= 1

          -  Women of child-bearing potential must have a negative pregnancy test within 30 hours
             before initiation of study drug dosing. Female subjects of reproductive potential must
             agree to avoid pregnancy throughout the study and for up to 3 months following
             discontinuation of study drug. Male subjects must agree to avoid conceiving a child
             throughout the study and for up to 3 months following discontinuation of study drug;

          -  Hemoglobin &gt;/= 8.0 gm/dL

          -  Absolute neutrophil count &gt;/= 1500

          -  Platelet count &gt;/= 100,000

          -  Glomerular Filtration Rate &gt; 50 mL/min calculated by the Cockcroft-Gault equation

          -  Total bilirubin &lt;/= 2.0 times the upper limit of normal unless the patient has
             Gilbert's syndrome

          -  Aspartate aminotransferase and Alanine Aminotransferase &lt;/= 2.5 times the upper limit
             of normal

          -  No other current malignancy, other than basal cell skin cancer, squamous cell skin
             cancer, in situ cervical cancer, ductal or lobular in situ of the breast. Patients
             with other malignancies are eligible if they have been continuously disease-free for
             &gt;/= 3 years prior to screening for this protocol.

          -  Age of 18 or older

          -  Ability and willingness to give informed consent

          -  Subjects must in the opinion of the Investigator be capable of complying with this
             protocol.

        Exclusion Criteria:

          -  Acute treatment for an infection or other serious medical illness within 14 days prior
             to study entry

          -  Major surgery within 3 weeks prior to study entry

          -  Known hypersensitivity to cisplatin or cetuximab

          -  Patients who have any severe or uncontrolled medical conditions or other conditions
             that could affect their participation in this study, including: unstable angina,
             serious uncontrolled cardiac arrhythmia, active acute or uncontrolled infectious
             disorder, or myocardial infarction &lt;/= 6 months prior to study entry.

          -  Female patients who are pregnant or breast feeding, or adults who are of reproductive
             potential and are unwilling to refrain from conceiving a child during study treatment.

          -  Patients unwilling to comply with the protocol, or provide informed consent

          -  Psychiatric illness that would limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F Deeken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprhensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>June 3, 2014</results_first_submitted>
  <results_first_submitted_qc>September 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2014</results_first_posted>
  <last_update_submitted>September 26, 2014</last_update_submitted>
  <last_update_submitted_qc>September 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>genetic testing</keyword>
  <keyword>cisplatin</keyword>
  <keyword>erbitux</keyword>
  <keyword>radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cisplatin</title>
          <description>Intensity modulated radiation with concurrent cisplatin
platinum plus radiation: Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy</description>
        </group>
        <group group_id="P2">
          <title>Cetuximab</title>
          <description>Intensity modulated radiation therapy with concurrent cetuximab
cetuximab plus radiation therapy: Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>male, caucasian, adult over 18</population>
      <group_list>
        <group group_id="B1">
          <title>Cisplatin</title>
          <description>Intensity modulated radiation with concurrent cisplatin
platinum plus radiation: Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy</description>
        </group>
        <group group_id="B2">
          <title>Cetuximab</title>
          <description>Intensity modulated radiation therapy with concurrent cetuximab
cetuximab plus radiation therapy: Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Returning Genetic Testing Results in a Timely Manner to the Treating Physician</title>
        <description>Feasibility is defined as follows:
- Patients' genetic test results are returned to the treating physician within 3 days</description>
        <time_frame>20 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin</title>
            <description>Intensity modulated radiation with concurrent cisplatin
platinum plus radiation: Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab</title>
            <description>Intensity modulated radiation therapy with concurrent cetuximab
cetuximab plus radiation therapy: Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Returning Genetic Testing Results in a Timely Manner to the Treating Physician</title>
          <description>Feasibility is defined as follows:
- Patients' genetic test results are returned to the treating physician within 3 days</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="3"/>
                    <measurement group_id="O2" value="3" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cisplatin</title>
          <description>Intensity modulated radiation with concurrent cisplatin
platinum plus radiation: Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy</description>
        </group>
        <group group_id="E2">
          <title>Cetuximab</title>
          <description>Intensity modulated radiation therapy with concurrent cetuximab
cetuximab plus radiation therapy: Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr John Deeken, PI</name_or_title>
      <organization>Inova Health Care System</organization>
      <phone>703 776 8161</phone>
      <email>john.deeken@inova.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

